Mild Cognitive Impairment
Conditions
Brief summary
NMDA neurotransmission plays an important role in learning and memory. NMDA receptors were found to decrease in the frontal lobe and hippocampus of mild cognitive impairment. This study is a randomized, double-blind, placebo-controlled drug trial. All subjects will be allocated randomly to 2 groups: (1) NMDA-enhancer: DAOIB group (starting dose: 250-500 mg/d); (2) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOIB may yield better efficacy than placebo for cognitive function in patients with mild cognitive impairment.
Interventions
DRUGDAOIB
DRUGPlacebo
Sponsors
Chang Gung Memorial Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of mild cognitive impairment * MMSE between 17-26 * CDR 0.5
Exclusion criteria
* Hachinski Ischemic Score \> 4 * Substance abuse/dependence * Parkinson disease, epilepsy, dementia with psychotic features * Major depressive disorder * Major physical illnesses * Severe visual or hearing impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24 | week 0, 8, 16, 24 |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in speed of processing (Category Fluency) at week 24 | week 0, 24 |
| Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24 | week 8, 16, 24 |
| Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24 | week 0, 24 |
| Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24 | week 0, 24 |
Countries
Taiwan
Outcome results
None listed